FairJourney Bio

FairJourney Bio’s antibody engineering work is advancing a tumor-conditional IL-12 approach designed to activate potent cytokine signaling more selectively within the tumor microenvironment, potentially addressing one of IL-12 therapy’s longstanding toxicity challenges. Representative image.

Pharma & Biotech

Can FairJourney Bio’s reversible antibody switch solve IL-12’s decades-old toxicity problem?

by Pallavi Madhiraju
August 20, 2026
0 Comments

FairJourney Bio engineers a tumor-conditional IL-12 switch designed to limit systemic exposure and localize cytokine activation in solid tumors.

Read More